Almirall announces Danish launch of MC2 Therapeutics-developed psoriasis cream

Almirall is launching psoriasis cream Wynzora in Denmark. The treatment has been inlicensed from Danish firm MC2 Therapeutics, where the CEO says ”it is a special feeling” to see Wynzora launched in its home country.

Photo: Mikkel Aabenhus Hemmingsen / MedWatch

Spanish dermatology firm Almirall is launching Wynzora, a plaque psoriasis cream developed by Danish firm MC2 Therapeutics, in Denmark, the firm has announced in a press release.

Almirall was granted European licensing rights to Wynzora last year, and has already launched the treatment in Germany, Spain and the UK earlier this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs